Insight

Aug 23, 2024, 05:20

Min-Han Tan: First precision oncology study involving comprehensive tissue and liquid NGS profiling for women with African ancestry

Min-Han Tan, Founding CEO at Lucence, shared a post by Lucence on LinkedIn:

“African women with breast cancer are a neglected population.

Glad we could collaborate with Yemaachi Biotech and Cape Coast Teaching Hospital in Ghana, in AMBER-01, the first precision oncology study involving comprehensive tissue and liquid NGS profiling for women with African ancestry.

I found it insightful that liquid biopsy achieved a much higher success in molecular profiling (100%) than tissue profiling (30%), with many treatable alterations (PIK3CA, BRCA, HER2).

This represents a real-world opportunity to improve overall cancer care through both greater access to liquid biopsy, and optimizing pathology laboratory workflows.

I learnt a lot from this effort. With much thanks to Yaw Bediako and his team!

Read the article here.”

Quoting Lucence’s post:

“Breast cancer is a challenging disease, and even more so for African women, who represent a neglected population.

In a world where optimal cancer care means identification of the right targets, so that drugs are useful and not futile, women of African ancestry typically have less access to both investigations and treatments.

It is thus critical to get things right to ensure diversity of cancer care.

AMBER-01 is the first comprehensive precision oncology study in Africa, where women with breast cancer receive both combined tissue and liquid profiling.

Key findings:

Ghanaian women with metastatic breast cancer have a diverse range of actionable alterations, treatable with the right drugs.
Liquid biopsy succeeded in delivering useful molecular sequencing results in 100% of Ghanaian women, compared to traditional tissue sampling for only 30% of women.

We’re proud to collaborate with Yemaachi Biotech and Cape Coast Teaching Hospital on this meaningful effort to bring better care to women of African ancestry!”

Source: Min-Han Tan/LinkedIn and Lucence/LinkedIn